

CDER Product-Specific Guidances Withdrawn Listing

Updated May 20, 2022

ACTIVE INGREDIENT	TYPE OF GUIDANCE	ROUTE AND DOSAGE FORM	RLD	DATE PSG POSTED OR REVISED	FEDERAL REGISTER NOTICE DATE
BUTENAFINE HYDROCHLORIDE	Draft	Topical Cream	21408	3/1/2012	2/1/2015
LEVONORGESTREL	Draft	IUD	203159	4/1/2014	10/1/2014
LORCASERIN HYDROCHLORIDE	Draft	Oral Tablet	022529	3/1/2015	3/4/2021
LORCASERIN HYDROCHLORIDE	Draft	Oral Tablet, ER	208524	5/1/2017	3/4/2021
LOVASTATIN; NIACIN	Draft	Oral Tablet, ER	021249	7/1/2009	4/18/2016
NIACIN; SIMVASTATIN	Draft	Oral Tablet, ER	022078	10/1/2011	4/18/2016